These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7507729)

  • 1. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors.
    Brugger W; Bross KJ; Glatt M; Weber F; Mertelsmann R; Kanz L
    Blood; 1994 Feb; 83(3):636-40. PubMed ID: 7507729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
    Brugger W; Birken R; Bertz H; Hecht T; Pressler K; Frisch J; Schulz G; Mertelsmann R; Kanz L
    Br J Haematol; 1993 Jul; 84(3):402-7. PubMed ID: 7692928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex vivo expansion of CD34+ peripheral blood progenitor cells: implications for the expansion of contaminating epithelial tumor cells.
    Vogel W; Behringer D; Scheding S; Kanz L; Brugger W
    Blood; 1996 Oct; 88(7):2707-13. PubMed ID: 8839866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone.
    Franklin WA; Glaspy J; Pflaumer SM; Jones RB; Hami L; Martinez C; Murphy JR; Shpall EJ
    Blood; 1999 Jul; 94(1):340-7. PubMed ID: 10381531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer.
    Elias AD; Ayash L; Anderson KC; Hunt M; Wheeler C; Schwartz G; Tepler I; Mazanet R; Lynch C; Pap S
    Blood; 1992 Jun; 79(11):3036-44. PubMed ID: 1350229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin.
    Brugger W; Henschler R; Heimfeld S; Berenson RJ; Mertelsmann R; Kanz L
    Blood; 1994 Sep; 84(5):1421-6. PubMed ID: 7520769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emergence of peripheral blood progenitor cells to support intensive chemotherapy for patients with breast cancer.
    Demetri GD
    Pharmacotherapy; 1996; 16(3 Pt 2):94S-100S. PubMed ID: 8726588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of PBPC mobilization by cyclophosphamide, as compared with that by epirubicin/paclitaxel followed by G-CSF support: implications for optimal timing of PBPC harvest.
    Dettke M; Greinix HT; Kalhs P; Kührer I; Worel N; Höcker P
    Transfusion; 2001 May; 41(5):681-6. PubMed ID: 11346706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer.
    Burns LJ; Weisdorf DJ; DeFor TE; Repka TL; Ogle KM; Hummer C; Miller JS
    Exp Hematol; 2000 Jan; 28(1):96-103. PubMed ID: 10658681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting progenitor cell yields using three tandem leukaphereses in previously treated malignancies.
    Lin JS; Tzeng CH; Hu HY; Yung CH
    Zhonghua Yi Xue Za Zhi (Taipei); 1998 Dec; 61(12):700-7. PubMed ID: 9884442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.
    Peters WP; Rosner G; Ross M; Vredenburgh J; Meisenberg B; Gilbert C; Kurtzberg J
    Blood; 1993 Apr; 81(7):1709-19. PubMed ID: 7681699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting.
    Lopez M; Lemoine FM; Firat H; Fouillard L; Laporte JP; Lesage S; Isnard F; Stachowiak J; Ferrer-Le Coeur F; Morel P; Najman A; Douay L; Gorin NC
    Blood; 1997 Oct; 90(7):2830-8. PubMed ID: 9326252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy.
    Fruehauf S; Haas R; Conradt C; Murea S; Witt B; Möhle R; Hunstein W
    Blood; 1995 May; 85(9):2619-26. PubMed ID: 7537123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization.
    Gajewski JL; Rondon G; Donato ML; Anderlini P; Korbling M; Ippoliti C; Benyunes M; Miller LL; LaTemple D; Jones D; Ashby M; Hellmann S; Durett A; Lauppe J; Geisler D; Khouri IF; Giralt SA; Andersson B; Ueno NT; Champlin R
    Biol Blood Marrow Transplant; 2002; 8(10):550-6. PubMed ID: 12434950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of granulocyte colony-stimulating factor-induced mobilization of circulating progenitor cells by seven-day pretreatment with interleukin-3.
    Geissler K; Peschel C; Niederwieser D; Strobl H; Goldschmitt J; Ohler L; Bettelheim P; Kahls P; Huber C; Lechner K; Höcker P; Kolbe K
    Blood; 1996 Apr; 87(7):2732-9. PubMed ID: 8639889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin.
    Brugger W; Möcklin W; Heimfeld S; Berenson RJ; Mertelsmann R; Kanz L
    Blood; 1993 May; 81(10):2579-84. PubMed ID: 7683923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.
    Gehling UM; Ryder JW; Hogan CJ; Hami L; McNiece I; Franklin W; Williams S; Helm K; King J; Shpall EJ
    Exp Hematol; 1997 Oct; 25(11):1125-39. PubMed ID: 9328449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison.
    Pierelli L; Perillo A; Greggi S; Salerno G; Panici PB; Menichella G; Fattorossi A; Leone G; Mancuso S; Scambia G
    J Clin Oncol; 1999 Apr; 17(4):1288. PubMed ID: 10561191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
    Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
    Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of preharvest tumor cell contamination in bone marrow or blood does not predict resultant tumor cell contamination of granulocyte colony-stimulating factor mobilized stem cells.
    Krüger W; Kröger N; Tögel F; Badbaran A; Renges H; Gieseking F; Gutensohn K; Jänicke F; Zander AR
    J Hematother Stem Cell Res; 2001 Apr; 10(2):303-7. PubMed ID: 11359677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.